Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma

Background/Aim: To evaluate the association between baseline [18F]FDG-PET/CT tumor burden parameters and disease progression rate after first-line target therapy or immunotherapy in advanced melanoma patients. Materials and Methods: Forty four melanoma patients, who underwent [18F]FDG-PET/CT before...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Virginia Liberini, Marco Rubatto, Riccardo Mimmo, Roberto Passera, Francesco Ceci, Paolo Fava, Luca Tonella, Giulia Polverari, Adriana Lesca, Marilena Bellò, Vincenzo Arena, Simone Ribero, Pietro Quaglino, Désirée Deandreis
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	immune checkpoint inhibitors PD-1 PD-L1 CTLA-4 immunotherapy target therapy Medicine R
Acceso en línea:	https://doaj.org/article/066e395753a74684b6a1ceafa6566f8f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:066e395753a74684b6a1ceafa6566f8f
record_format	dspace
spelling	oai:doaj.org-article:066e395753a74684b6a1ceafa6566f8f2021-11-11T17:37:36ZPredictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma10.3390/jcm102149942077-0383https://doaj.org/article/066e395753a74684b6a1ceafa6566f8f2021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4994https://doaj.org/toc/2077-0383Background/Aim: To evaluate the association between baseline [18F]FDG-PET/CT tumor burden parameters and disease progression rate after first-line target therapy or immunotherapy in advanced melanoma patients. Materials and Methods: Forty four melanoma patients, who underwent [18F]FDG-PET/CT before first-line target therapy (28/44) or immunotherapy (16/44), were retrospectively analyzed. Whole-body and per-district metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. Therapy response was assessed according to RECIST 1.1 on CT scan at 3 (early) and 12 (late) months. PET parameters were compared using the Mann–Whitney test. Optimal cut-offs for predicting progression were defined using the ROC curve. PFS and OS were studied using Kaplan–Meier analysis. Results: Median (IQR) MTVwb and TLGwb were 13.1 mL and 72.4, respectively. Non-responder patients were 38/44, 26/28 and 12/16 at early evaluation, and 33/44, 21/28 and 12/16 at late evaluation in the whole-cohort, target, and immunotherapy subgroup, respectively. At late evaluation, MTVbone and TLGbone were higher in non-responders compared to responder patients (all <i>p</i> < 0.037) in the whole-cohort and target subgroup and MTVwb and TLGwb (all <i>p</i> < 0.022) in target subgroup. No significant differences were found for the immunotherapy subgroup. No metabolic parameters were able to predict PFS. Controversially, MTVlfn, TLGlfn, MTVsoft + lfn, TLGsoft + lfn, MTVwb and TLGwb were significantly associated (all <i>p</i> < 0.05) with OS in both the whole-cohort and target therapy subgroup. Conclusions: Higher values of whole-body and bone metabolic parameters were correlated with poorer outcome, while higher values of whole-body, lymph node and soft tissue metabolic parameters were correlated with OS.Virginia LiberiniMarco RubattoRiccardo MimmoRoberto PasseraFrancesco CeciPaolo FavaLuca TonellaGiulia PolverariAdriana LescaMarilena BellòVincenzo ArenaSimone RiberoPietro QuaglinoDésirée DeandreisMDPI AGarticleimmune checkpoint inhibitorsPD-1PD-L1CTLA-4immunotherapytarget therapyMedicineRENJournal of Clinical Medicine, Vol 10, Iss 4994, p 4994 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune checkpoint inhibitors PD-1 PD-L1 CTLA-4 immunotherapy target therapy Medicine R
spellingShingle	immune checkpoint inhibitors PD-1 PD-L1 CTLA-4 immunotherapy target therapy Medicine R Virginia Liberini Marco Rubatto Riccardo Mimmo Roberto Passera Francesco Ceci Paolo Fava Luca Tonella Giulia Polverari Adriana Lesca Marilena Bellò Vincenzo Arena Simone Ribero Pietro Quaglino Désirée Deandreis Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
description	Background/Aim: To evaluate the association between baseline [18F]FDG-PET/CT tumor burden parameters and disease progression rate after first-line target therapy or immunotherapy in advanced melanoma patients. Materials and Methods: Forty four melanoma patients, who underwent [18F]FDG-PET/CT before first-line target therapy (28/44) or immunotherapy (16/44), were retrospectively analyzed. Whole-body and per-district metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. Therapy response was assessed according to RECIST 1.1 on CT scan at 3 (early) and 12 (late) months. PET parameters were compared using the Mann–Whitney test. Optimal cut-offs for predicting progression were defined using the ROC curve. PFS and OS were studied using Kaplan–Meier analysis. Results: Median (IQR) MTVwb and TLGwb were 13.1 mL and 72.4, respectively. Non-responder patients were 38/44, 26/28 and 12/16 at early evaluation, and 33/44, 21/28 and 12/16 at late evaluation in the whole-cohort, target, and immunotherapy subgroup, respectively. At late evaluation, MTVbone and TLGbone were higher in non-responders compared to responder patients (all <i>p</i> < 0.037) in the whole-cohort and target subgroup and MTVwb and TLGwb (all <i>p</i> < 0.022) in target subgroup. No significant differences were found for the immunotherapy subgroup. No metabolic parameters were able to predict PFS. Controversially, MTVlfn, TLGlfn, MTVsoft + lfn, TLGsoft + lfn, MTVwb and TLGwb were significantly associated (all <i>p</i> < 0.05) with OS in both the whole-cohort and target therapy subgroup. Conclusions: Higher values of whole-body and bone metabolic parameters were correlated with poorer outcome, while higher values of whole-body, lymph node and soft tissue metabolic parameters were correlated with OS.
format	article
author	Virginia Liberini Marco Rubatto Riccardo Mimmo Roberto Passera Francesco Ceci Paolo Fava Luca Tonella Giulia Polverari Adriana Lesca Marilena Bellò Vincenzo Arena Simone Ribero Pietro Quaglino Désirée Deandreis
author_facet	Virginia Liberini Marco Rubatto Riccardo Mimmo Roberto Passera Francesco Ceci Paolo Fava Luca Tonella Giulia Polverari Adriana Lesca Marilena Bellò Vincenzo Arena Simone Ribero Pietro Quaglino Désirée Deandreis
author_sort	Virginia Liberini
title	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
title_short	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
title_full	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
title_fullStr	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
title_full_unstemmed	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
title_sort	predictive value of baseline [18f]fdg pet/ct for response to systemic therapy in patients with advanced melanoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/066e395753a74684b6a1ceafa6566f8f
work_keys_str_mv	AT virginialiberini predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT marcorubatto predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT riccardomimmo predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT robertopassera predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT francescoceci predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT paolofava predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT lucatonella predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT giuliapolverari predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT adrianalesca predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT marilenabello predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT vincenzoarena predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT simoneribero predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT pietroquaglino predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma AT desireedeandreis predictivevalueofbaseline18ffdgpetctforresponsetosystemictherapyinpatientswithadvancedmelanoma
_version_	1718432041426485248

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma

Ejemplares similares